Clinical Trial Update: Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating a novel therapy that targets reactive oxygen species production for Fuchs Endothelial Corneal Dystrophy, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fuchs Endothelial Corneal Dystrophy

Snippet

Sponsor: Massachusetts Eye and Ear Infirmary | Conditions: Fuchs Endothelial Corneal Dystrophy | Phase 2 | Status: RECRUITING